Ajanta Pharmaceuticals Ltd.
Research Ajanta Pharmaceuticals Ltd. (AJANTPHARM.NS) on Bullrun: market cap INR 415.99B, P/E 36.7, dividend yield 1.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAJANTPHARM.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 415.99B
- P/E36.7
- Dividend yield1.8%
- Financial periodQ2 2026
- RevenueINR 16.26B
- Net incomeINR 3.34B
- Gross margin79.8%
Valuation Snapshot
latest market cap is INR 415.99B; P/E is 36.7; dividend yield is 1.8%.
Peer valuation comparison
Latest P/E is 36.67x versus a Healthcare sector median of 21.74x (68.6% above).
Latest dividend yield is 1.8% versus a Healthcare sector median of 2.4% (25.0% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 415.99B | 36.7 | 1.9% | 64 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 64 INR, yield 1.8%.
About Ajanta Pharmaceuticals Ltd.
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ajanta Pharmaceuticals Ltd.'s market cap?
Ajanta Pharmaceuticals Ltd.'s market capitalization is INR 415.99B.
What is Ajanta Pharmaceuticals Ltd.'s P/E ratio?
Ajanta Pharmaceuticals Ltd.'s price-to-earnings (P/E) ratio is 36.7.
Does Ajanta Pharmaceuticals Ltd. pay a dividend?
Ajanta Pharmaceuticals Ltd. has a dividend yield of 1.8%.
What does Ajanta Pharmaceuticals Ltd. do?
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management.